Vanguard Group’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Vanguard Group’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-1,554,979	Closed	-$152M	–	4217
2015 Q1	$152M	Buy	1,554,979 +234,058	+18%	+$24.8M	0.01%	1205
2014 Q4	$123M	Buy	1,320,921 +26,900	+2%	+$2.12M	0.01%	1274
2014 Q3	$89M	Buy	1,294,021 +53,640	+4%	+$3.84M	0.01%	1438
2014 Q2	$130M	Buy	1,240,381 +176,729	+17%	+$15M	0.01%	1226
2014 Q1	$88.3M	Buy	1,063,652 +108,024	+11%	+$9.99M	0.01%	1436
2013 Q4	$61.8M	Buy	955,628 +88,023	+10%	+$5.22M	0.01%	1651
2013 Q3	$54.9M	Buy	867,605 +211,365	+32%	+$10.4M	0.01%	1665
2013 Q2	$27.6M	Buy	+656,240	New	+$29.9M	﹤0.01%	1949

Vanguard Group's GEVA Position: Q2 2015 in Review

Vanguard Group sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 1,554,979 shares — an estimated $152M sold.

Vanguard Group first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $152M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

Vanguard Group reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
Vanguard Group sold 1,554,979 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $152M.
Vanguard Group first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
Vanguard Group's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $152M in Q1 2015.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Vanguard Group's 13F filing for Q2 2015, filed 13 Aug 2015.